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Introduction
B cell depletion therapies (BCDTs), such as rituximab, are efficacious in numerous immune-mediated dis-
eases, including rheumatoid arthritis and multiple sclerosis (1). Current BCDTs target CD20 and eliminate 
B cells but not antibody-producing plasma cells because they do not express CD20 (2). Indeed, most auto-
antibodies remain present after depletion despite clinical response (3), suggesting that B cells may contrib-
ute to tissue injury in an antibody-independent manner.
Since the first reports in 2004 of  the successful treatment of  steroid-sensitive nephrotic syndromes 
(SSNS), such as minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS), using 
rituximab (4–6), there are now over 200 publications in the literature. The majority of  these are anecdotal 
reports and small uncontrolled studies, but the consensus today is that BCDTs are likely efficacious for ste-
roid-sensitive, relapsing forms of  disease. By definition, autoreactive antibodies and immune complexes are 
absent in MCD and FSGS (7). Current therapies are based on the idea that immune dysfunction, potential-
ly involving T cells, is involved in the pathogenesis of  these diseases, as first proposed by Shalhoub (8). This 
idea is supported by the responsiveness of  most MCD/FSGS patients to immunosuppressive therapies. 
Furthermore, the clinical observation that some patients with nephrotic syndrome respond to plasmapher-
esis suggests that a soluble, circulating factor may be responsible (9, 10). The efficacy of  BCDTs supports 
an immune origin of  disease for some nephrotic patients. However, a specific mechanism to explain disease 
pathogenesis is still lacking.
Given the absence of  pathogenic antibodies in these diseases, a role for B cells would need to be 
antibody independent. In recent years, antibody-independent functions have been ascribed to B cells. 
Mouse models of  systemic lupus erythematosus (SLE) demonstrate that B cells are as important as 
The efficacy of B cell depletion therapies in diseases such as nephrotic syndrome and rheumatoid 
arthritis suggests a broader role in B cells in human disease than previously recognized. In some of 
these diseases, such as the minimal change disease subtype of nephrotic syndrome, pathogenic 
antibodies and immune complexes are not involved. We hypothesized that B cells, activated in 
the kidney, might produce cytokines capable of directly inducing cell injury and proteinuria. To 
directly test our hypothesis, we targeted a model antigen to the kidney glomerulus and showed that 
transfer of antigen-specific B cells could induce glomerular injury and proteinuria. This effect was 
mediated by IL-4, as transfer of IL-4–deficient B cells did not induce proteinuria. Overexpression 
of IL-4 in mice was sufficient to induce kidney injury and proteinuria and could be attenuated by 
JAK kinase inhibitors. Since IL-4 is a specific activator of STAT6, we analyzed kidney biopsies and 
demonstrated STAT6 activation in up to 1 of 3 of minimal change disease patients, suggesting IL-4 
or IL-13 exposure in these patients. These data suggest that the role of B cells in nephrotic syndrome 
could be mediated by cytokines.
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antigen-presenting cells for autoreactive T cells (11). B cells can also make cytokines that can either pro-
mote or inhibit inflammation (12, 13). Cytokines produced by B cells are required for the development 
of  lymph node and ectopic lymphoid follicles, can amplify T cell responses, and can suppress arthritis, 
colitis, and experimental autoimmune encephalitis in mice (14, 15).
The cardinal pathologic feature of  nephrotic diseases is foot process effacement of  the glomerular 
podocyte. The glomerulus houses the glomerular filtration barrier, where a highly differentiated epithe-
lial cell known as the podocyte forms the final cellular barrier for the filtration of  blood and generation 
of  urine. Podocytes have a specialized architecture characterized by interdigitating cellular arborizations 
(foot processes) that form a mesh-like structure on the urinary aspect of  the glomerular capillaries. In all 
cases of  active proteinuria, podocytes exhibit a simplification and flattening/retraction of  the podocyte foot 
processes, a finding termed foot process effacement. Given the lack of  cellular inflammation or immune 
complexes in MCD and FSGS, the likeliest scenario for an immunologic cause would be a factor secreted 
by an immune cell.
In this study, we directly tested whether cytokines produced by B cells could induce podocyte foot pro-
cess effacement and proteinuria. Using an in vitro assay of  podocyte injury, we identified IL-4 as a cytokine 
capable of  stimulating membrane ruffling of  podocytes and detachment of  podocytes from the basement 
membrane in vitro. Using a method of  in vivo gene delivery, we confirmed that IL-4 is sufficient to induce 
foot process effacement and proteinuria when overexpressed in mice. To determine whether B cells acti-
vated locally in the kidney could make enough IL-4 to induce foot process effacement, we planted a B cell 
antigen on the glomerular basement membrane (GBM) and showed that antigen-specific B cells could 
induce foot process effacement in an IL-4–dependent fashion. Finally, we found evidence of  IL-4 receptor 
signaling in the kidneys in some patients with MCD. Taken together, these findings reveal a mechanism for 
the efficacy of  anti–B cell therapies in the treatment of  steroid-sensitive nephrotic diseases. These results 
also suggest that IL-4 is a potential nephrotic factor and therapeutic target.
Results
Rituximab does not bind SMPDL3B in nonfixed cells. It was recently proposed that the effect of rituximab on 
nephrotic syndrome is not due to B cells but is instead mediated by its off-target binding to sphingomyelin-phos-
phodiesterase-acid-like-3b (SMPDL3B) expressed on podocytes (16). To confirm the binding of SMPDL3B by 
rituximab, we overexpressed HA-tagged SMPDL3B in 293T cells that do not endogenously express either 
CD20 or SMPDL3B. Expression and membrane localization of HA-SMPDL3B were confirmed by immuno-
blotting and immunofluorescence with HA and SMPDL3B antibodies (Figure 1A and Supplemental Figure 1, 
A and B; see complete unedited blots in the supplemental material; supplemental material available online with 
this article; https://doi.org/10.1172/jci.insight.81836DS1). Modeling suggested that the N-terminal HA-tag 
is spatially separated from the SMPDL3B epitope (156ELWKPW161) reported to be recognized by rituximab 
(Supplemental Figure 1C).
Figure 1. Rituximab does not bind SMPDL3B in nonfixed samples. (A) Western blot of transfected 293T and Raji cells. Whole-cell lysates were subjected 
to SDS-PAGE, followed by immunoblotting with antibodies as indicated. β-Actin was used as loading control. (B) Rituximab does not bind to SMPDL3B 
in nonfixed cells. Nonfixed or PFA-fixed 293T cells expressing HA-SMPDL3B were stained with α-HA-AF488 and rituximab-AF647 and analyzed by flow 
cytometry. Data are representative of 3 independent experiments.
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To mimic the in vivo setting, we incubated nonfixed cells with rituximab and an anti-HA tag antibody. 
In 293T cells expressing HA-SMPDL3B, staining was detected with an anti-HA antibody but not with rit-
uximab (Figure 1B and Supplemental Figure 2, A and B). Notably, when cells were fixed with paraformal-
dehyde (PFA) prior to antibody staining, we observed marked binding of  rituximab to cells, regardless of  
SMPDL3B expression (Figure 1B and Supplemental Figure 2, A and B). Similar results were obtained with 
HeLa cells overexpressing HA-SMPDL3B (Supplemental Figure 3, A and B; see complete unedited blots in 
the supplemental material). Binding of  rituximab to CD20 was confirmed by staining Raji cells (Supplemen-
tal Figure 1D). These results suggest that rituximab does not bind to SMPDL3B in vivo and that the binding 
previously reported is not specific. This suggests that the efficacy of  rituximab in nephrotic kidney diseases 
is not through its ability to bind and directly modulate podocytes. We therefore considered antibody-inde-
pendent B cell functions.
IL-4 and IL-13 induced membrane ruffling in cultured podocytes and foot process retraction in kidney fragments in vitro. 
B cells secrete a diverse array of cytokines upon activation, including IFN-γ, TNF-α, IL-4, and IL-13 (13, 17–
20). Conversely, podocytes express cytokine receptors, including receptors for IFN-γ, TNF-α, IL-4, and IL-13 
(21–23). Therefore, we tested individual cytokines for their ability to induce foot process effacement in vitro. 
Figure 2. IL-4 induces podocyte membrane ruffling and widespread foot process retraction. (A) Differential interference contrast live-cell imaging was 
used to obtain kymographs from individual differentiated cultured murine podocytes. Each cell was imaged individually from separate podocyte cultures. 
Representative kymographs (time = 20 minutes) before (left column) and after (right column) the addition of IL-4 (10 ng/ml, top row) or IL-4 with anti–IL-4 
antibody (5 μg/ml, bottom row) are shown. IL-4 caused pronounced membrane ruffling that was abrogated by anti–IL-4 treatment (also see Supplemen-
tal Videos 1 and 2). Original magnification, ×~1,100. (B) Kymograph analysis was used to quantitate actin spike lengths (ruffling index) of 5 locations per 
cultured podocyte for the cytokines tested (IL-13: 10 ng/ml, IFN-γ: 100 ng/ml, TNF-α: 10 ng/ml). IL-4 and IL-13 have enhanced membrane ruffling dynam-
ics. IL-4 promoted an equivalent level of ruffling as a known activator of Rac, EGF (20 ng/ml), which was reversed with anti–IL-4 antibody. Each symbol 
represents the average relative cell membrane displacement over time at 5 regions of a single cell. Each cell mean ± SD of 3 experiments, with 3–4 cells/
experiment (total of 10 cells analyzed/group). (C) Representative scanning electron microscopy images of glomeruli from minced renal cortices incubated 
ex vivo for 20 minutes with IL-4 (10 ng/ml), IL-4 with anti–IL-4 antibody (5 μg/ml), TNF-α (10 ng/ml), or positive control EGF (20 ng/ml). IL-4 treatment 
induced massive foot process retractions similar to that induced by EGF. TNF-α and IL-4 plus anti–IL-4 did not alter foot process morphology, consistent 
with the membrane ruffling data. Scale bar: 20 μm. *P < 0.001, **P < 0.005, ***P < 0.004, ****P < 0.03 by 1-way ANOVA with Bonferroni correction.
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We have proposed that the activation of the small GTPase Rac is the cell biological correlate for foot process 
effacement in vivo (24, 25). Rac is a member of the Rho family of small G proteins, which also includes Cdc42 
and Rho. Rac activation stimulates the formation of actin cytoskeletal structures that are associated with cell 
migration and membrane ruffling (26). Rac activation in podocytes acutely induces foot process effacement 
and proteinuria in mice (24, 25).
Cytokines were added to cultured murine podocytes, and differential interference contrast live-cell 
imaging of  individual cells in separate culture dishes was used to evaluate the response. Membrane ruffling 
was used as a surrogate for Rac activation, and kymograph analysis was used to quantitate membrane 
ruffling before and after addition of  the cytokine (25, 27). IL-4 and, to a lesser extent, IL-13 induced mem-
brane ruffling, while TNF-α and IFN-γ had no effect on membrane ruffling (Figure 2, A and B, and Sup-
plemental Videos 1 and 2). IL-4 stimulated a similar degree of  ruffling as EGF, a known activator of  Rac 
(28). The addition of  a neutralizing IL-4 antibody abrogated IL-4–induced membrane ruffling (Figure 2B), 
indicating that the effect was IL-4 specific.
Since cultured podocytes do not form foot processes, we minced murine renal cortices where the glomeruli 
are located and treated these fragments with cytokines to evaluate for abnormalities in foot process morpholo-
gy. Using scanning electron microscopy, we found that IL-4 induced severe foot process retractions, podocyte 
detachment, and exposure of the glomerular capillary wall, while TNF-α did not (Figure 2C). The changes 
induced by IL-4 were comparable to those induced by EGF and were blocked with anti–IL-4 antibody (Figure 
2C). These data confirmed the ability of IL-4 to directly induce podocyte damage in ex vivo renal cortex.
Figure 3. Mice treated with a plasmid encoding IL-4 
exhibited proteinuria, foot process abnormalities, 
and STAT6 activation in glomeruli. (A) 129X1/SvJ 
mice were hydrodynamically injected with either 
IL-4 piggyBac plus transposase vectors to induce 
IL-4 expression (IL-4 treated) or empty piggyBac 
plus transposase vectors (control). Representa-
tive Coomassie blue–stained SDS-PAGE. (B) Spot 
albumin/creatinine ratios of urine from control or 
IL-4–treated mice demonstrated proteinuria with IL-4 
expression. Urine was collected 12 hours after plasmid 
injection. (C) Serum IL-4 ELISA confirmed elevated 
expression of IL-4 in IL-4 gene–treated mice. Symbols 
represent individual mice, and bars represent the 
geographic mean in B and mean in C. Mean ± SD of 3 
experiments, with total of 5 mice/group. *P < 0.006, 
**P < 0.001 by 2-tailed Mann-Whitney. (D) Repre-
sentative scanning electron microscopy (scale bar: 1 
μm) revealed foot process retraction with focal foot 
process effacement in IL-4–treated mice compared 
with control. (E) Representative immunohistochemi-
cal analysis of glomerular pSTAT6 expression reveals 
substantial STAT6 phosphorylation and nuclear trans-
location in IL-4–treated mice (black arrows) compared 
with control. Original magnification, ×400. Data are 
representative of 4 independent experiments.
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IL-4 overexpression induces proteinuria and IL-4 signaling in the glomerulus in vivo, which is reduced with JAK1/3 
inhibition. To evaluate the role of  IL-4 in vivo, we expressed IL-4 in mice by injecting a plasmid based on a 
transposon expression system using hydrodynamic injection (29–31). In this system, the gene of  interest inte-
grates into the genome in a site-specific fashion, primarily in hepatocytes, allowing for efficient and high-lev-
el expression of  the introduced gene (32). Delivery of  the IL-4 gene induced marked proteinuria (Figure 3, 
A and B; see complete unedited blots in the supplemental material) with a severity that directly correlated with 
serum levels of  IL-4 (Figure 3C). No proteinuria was seen when a control targeting vector was administered. 
Scanning electron microscopy performed on kidneys 3 days after plasmid administration demonstrated 
blunted foot processes with scattered areas of  effacement (Figure 3D). In comparison, the foot processes of  
podocytes from control mice were normal. These data show that high serum levels of  IL-4 via its overexpres-
sion in the liver can directly induce podocyte foot process abnormalities and proteinuria in vivo.
IL-4 signals through the IL-4 receptor (IL-4Rα and common-γ chain) to activate the tyrosine kinases 
JAK1 and JAK3 and subsequently the transcription factor STAT6 (33). Kidney sections obtained from 
mice 24 hours following mock or IL-4 plasmid administration were stained for 6 (pSTAT6) using immu-
nohistochemistry (Figure 3E). IL-4 treatment strongly induced pSTAT6 within podocytes and other glo-
merular cells, with little to no staining detected in the glomeruli of  control mice. Based on the activation of  
STAT6, this supports the idea that podocytes can respond to IL-4 in vivo.
Since IL-4 utilizes the JAK1 and JAK3 kinases for signaling, we tested if  JAK1/3 inhibition could 
block IL-4–induced membrane ruffling in podocytes in vitro and the development of  proteinuria in vivo. 
A small-molecule inhibitor of  JAK1 and JAK3, tofacitinib, is approved for the treatment of  rheuma-
toid arthritis (34). Pretreatment of  cultured podocytes with the inhibitor significantly decreased mem-
brane ruffling induced by IL-4 (Figure 4, A and B). To assess its effects in vivo, mice were treated with 
the inhibitor twice daily, starting 1 day prior to IL-4 gene delivery. Treatment with the JAK inhibitor 
Figure 4. Inhibition of IL-4 signaling with JAK1/3 inhibitor abrogated ruffling and proteinuria in IL-4–treated mice. (A) Representative kymographs 
obtained by membrane ruffling and (B) quantification, as performed in Figure 1, from cultured podocytes treated with the JAK1/3 inhibitor tofacitinib (100 
nM, bottom row), which significantly attenuated IL-4–induced membrane ruffling compared with negative control (DMSO). Each symbol represents the 
average relative cell membrane displacement over time at 5 regions of a single cell. Mean ± SD of 2 experiments, with 2–3 cells/experiment (total of 5 cells 
analyzed/group). (C) Coomassie blue–stained SDS-PAGE and (D) spot albumin/creatinine ratios of urine from IL-4–treated mice treated with JAK1/3 inhibi-
tion, which significantly reduced IL-4–induced proteinuria. Urine was collected 24 hours after plasmid administration. Symbols represent individual mice, 
and bars represent the mean. Mean ± SEM of 2 experiments, with total of 5 mice/group. *P < 0.008 by 2-tailed Mann-Whitney.
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significantly attenuated the proteinuria induced by IL-4 (Figure 4, C and D; see complete unedited blots in 
the supplemental material). Thus, JAK1/3 inhibition can block the effects of  IL-4 on foot process efface-
ment and proteinuria.
Generation of  a B cell–dependent in vivo model of  proteinuria. We next wondered if  B cells could be acti-
vated in the glomerulus and whether they could produce sufficient IL-4 to induce podocyte foot process 
effacement and proteinuria in vivo. To test this hypothesis, we targeted a B cell antigen to the glomerular 
capillary wall, followed by an infusion of  antigen-specific B cells. We chose the soluble antigen hen egg 
lysozyme (HEL), as a B cell receptor–specific transgenic mouse exists for it (35). HEL has a high negative 
log dissociation constant (pKi) (~12) that allows it to enter the negatively charged glomerular filtration 
barrier, but its small size (14 kDa) allowed it to be freely filtered through the GBM. To trap HEL within the 
glomerular capillary wall, we conjugated it to biotin, allowing us to produce larger tetrameric aggregates 
using avidin (Figure 5A). The HEL multimers had a molecular weight greater than 120 kDa (Figure 5B; 
see complete unedited blots in the supplemental material), well above the size exclusion limit (~60–70 kDa) 
of  the glomerular filtration barrier. I.v. injection of  avidin/biotin/HEL complexes resulted in trapping of  
multimers in the GBM within 30 minutes (Figure 5C) and was stable up to a week after injection. HEL 
multimers were also detected in the liver and spleen (data not shown).
We next tested whether adoptive transfer of  polarized antigen-specific B cells could induce protein-
uria. B cells were polarized into B effector 2 (Be2) cells by activating them in the presence of  Th2-po-
larized cells (Figure 6A); then they were injected into mice i.v. (13, 36). Within 24 hours, mice became 
proteinuric, as detected qualitatively using SDS-PAGE of  urine samples or quantitatively using a uri-
nary albumin ELISA (Figure 6, B and C; see complete unedited blots in the supplemental material). 
The proteinuria was transient, peaking between 12 and 24 hours, and specific to IL-4, since transfer of  
antigen-specific B cells that were IL-4 deficient (IL-4–/–) did not induce proteinuria. IL-4–/– Be2 cells 
were only deficient in IL-4, and the other cytokines produced were made at the same levels as wild-
type B cells (Supplemental Figure 4). Circulating IL-4 was undetectable by ELISA in the mice injected 
with antigen-specific B cells, suggesting that the effect was due to local B cell activation and release 
of  IL-4 (data not shown). This was supported by 2-photon imaging of  B cells in the kidney (37). 
Figure 5. Multimerized hen egg lysozyme embedded within the glomerular basement membrane following i.v. injection. (A) The production of multim-
erized hen egg lysozyme (HEL). Monomeric HEL was biotinylated and then complexed with avidin to form multimers. (B) Representative Coomassie blue–
stained SDS-PAGE of monomeric and multimerized HEL demonstrated multimerized complexes of at least 120 kDa were formed. (C) Immunofluorescence 
microscopy images (green = HEL complex, blue = DAPI) of frozen sections from kidneys of mice injected with multimerized HEL (left: 30 minutes after 
injection, center: 7 days after injection) or monomeric HEL (right: 30 minutes after injection) and stained with anti-HEL antibody. Monomeric HEL was not 
visible in glomeruli, while multimerized HEL was found in the glomeruli up to 7 days after injection. Glomeruli are outlined in circles. Original magnifica-
tion, ×20. Data are representative of 3 independent experiments.
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After injection of  antigen, mice were anesthetized and a kidney was exteriorized. Injection (i.v.) of  flu-
orescent dextran labeled blood vessels and allowed us to identify glomeruli. In the absence of  cognate 
antigen, labeled HEL-specific B cells trafficked rapidly through the glomerular capillaries. In contrast, 
when antigen was present, B cells entered the glomerular capillaries and arrested their movement 
within the glomeruli (Figure 6D and Supplemental Videos 3 and 4). B cell arrest within the glomerular 
capillaries when antigen was present suggests that in situ recognition of  antigen leads to B cell activa-
tion and cytokine secretion.
Since the activation of  B cells within glomeruli could induce inflammatory changes, we performed 
light and immunofluorescence microscopy to assess for pathologic changes. We observed no obvious 
morphologic alterations in the glomeruli of  proteinuric mice by light microscopy at all time points tested 
Figure 6. HEL-specific IL-4–secreting B cells generated proteinuria in mice treated with multimerized HEL. (A) HEL-specific B cells were either polarized 
in vitro into B effector 2 (Be2) cells to produce IL-4, or left unpolarized, and then stimulated through the B cell receptor with anti-μ antibody overnight. Only 
Be2-polarized B cells secreted IL-4 into the supernatant, as measured by ELISA. (B) Coomassie blue–stained SDS-PAGE and (C) spot albumin/creatinine ratios 
of urine from mice treated with multimerized HEL, followed by transfer of either Be2-polarized HEL-specific B cells or IL-4–deficient, Be2-polarized HEL-spe-
cific B cells. Proteinuria was observed only when B cells were capable of producing IL-4. Urine was collected 24 hours after B cell transfer. Symbols represent 
individual mice, and bars represent the mean. (D) Representative still images obtained from intravital 2-photon microscopy movies (Supplemental Videos 3 
and 4) of mice injected with PBS (top) or multimerized HEL (bottom), followed by the transfer of fluorescently labeled HEL-specific B cells. When glomerular 
HEL was present, HEL-specific B cells arrested within glomeruli. In the absence of HEL, B cell trafficking through glomeruli was not changed. Quantum dots 
were injected i.v. to identify glomeruli and vessels. Glomeruli are outlined in circles. Red: glomeruli and vessels; blue: renal tubules; yellow: HEL-specific B cells. 
Original magnification, ×20. Mean ± SD of 2 experiments, with a total of 5 mice/group. *P < 0.001, **P < 0.008 by 2-tailed Mann-Whitney.
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(Figure 7A). In addition, immunofluores-
cence staining of  sections from proteinuric 
mice showed no detectable immunoglobu-
lin or complement deposition in glomeruli 
(Figure 7B). Ultrastructural analysis of  the 
glomeruli using scanning electron microsco-
py confirmed the presence of  focal foot pro-
cess effacement in proteinuric mice, while 
nonproteinuric control mice had normal 
foot processes (Figure 7C). Thus, B cells, 
activated in the kidney, can induce protein-
uria and foot process effacement indepen-
dent of  antibodies and immune complexes.
Glomerular STAT6 activation occurs in a 
subset of  MCD patients. STAT6 phosphory-
lation is specific for signaling by IL-4 and 
IL-13. To test if  pSTAT6 can be detected 
in humans with nephrotic syndrome, we 
stained kidney biopsy sections from patients 
with MCD for STAT6 activation. Since 
most patients with MCD respond to initial 
treatment with glucocorticoids, patients are 
often biopsied only after treatment failure, 
limiting the availability of  naive biopsy tis-
sue. Such patients are also by definition ste-
roid resistant and not likely to be sensitive to 
BCDTs. Twenty-nine patients with MCD, in 
which a biopsy was obtained before initia-
tion of  treatment, were identified from the 
Renal Pathology Services at Washington 
University School of  Medicine, the Univer-
sity of  Michigan, and King’s College/Evelina Children’s Hospital (Supplemental Table 1). For controls, 
we stained 23 kidney biopsies obtained for conditions unrelated to nephrotic syndrome (see Methods 
for diagnoses). Two of  the twenty-nine MCD biopsies demonstrated strong glomerular pSTAT6 stain-
ing, and eight had weakly positive staining (see Methods for definitions). Of  23 controls, only one 
showed weakly positive pSTAT6 staining (Figure 8). While this is a small sample, these data support the 
hypothesis that IL-4 and/or IL-13 may be involved in some patients with MCD.
Figure 7. B cell–induced proteinuria generated 
foot process effacement. (A) Representative 
light microscopy of H&E-stained kidney sections 
from mice with B cell–induced proteinuria 
revealed no pathologic changes. Original mag-
nification, ×40. (B) Representative immunoflu-
orescence microscopy images of kidneys from 
mice with B cell–induced proteinuria (left) did 
not demonstrate immunoglobulin or comple-
ment component C3 in glomeruli compared to 
positive control nephrotoxic serum (right). (C) 
Representative scanning electron microscopy 
from kidneys showed focal foot process efface-
ment in mice with B cell–induced proteinuria 
(right) compared with control mice (left). Scale 
bar: 10 μm. Data are representative of 3 indepen-
dent experiments.
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Discussion
Since the first reports of  rituximab in the treatment of  nephrotic diseases in 2004, its use has become 
an important part of  the treatment armamentarium, especially for steroid-sensitive and relapsing 
forms of  MCD and FSGS. Since there is no known role for B cells in these diseases, how and why 
rituximab mediates its efficacy is a mystery. One potential explanation is the ability of  rituximab to 
directly bind to SMPDL3B on the podocyte (16), reversing changes in integrin affinity. Reports that 
ofatumumab, a CD20 antibody that binds to an epitope distinct from rituximab (38, 39), is also effica-
cious in patients with steroid-resistant FSGS (6) motivated us to reexamine this question. SMPDL3B, 
a protein expressed on podocytes but also broadly expressed on monocytes and gut epithelia, was ini-
tially proposed to bind to rituximab, as it contains a peptide sequence, in the reverse orientation, to an 
epitope identified in a screen for rituximab-binding sequences (40). Previous binding assays used fixed 
samples and amplification steps to visualize staining of  podocytes with rituximab, indicating that the 
binding is weak (16). Our data suggest that the binding is not specific, suggesting that B cell depletion 
is the mechanism of  action.
Figure 8. A subset of minimal change disease patients has activated glomerular STAT6. Representative immunohistochemistry of glomerular pSTAT6 
expression in selected MCD patients (described in Supplemental Table 1) and a control. Ten of twenty-nine MCD patients screened demonstrated pSTAT6 
staining (untreated MCD, arrows point to stained nuclei). Twenty-two of twenty-three healthy controls had no detectable pSTAT6 staining. Of 29 MCD 
patient samples stained for pSTAT6, 2 were strongly positive, 8 were weakly positive, and 19 were negative; of 22 controls samples stained for pSTAT6, 1 
was weakly positive and 22 were negative (P = 0.019). Original magnification, ×400.I
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Nephrotic diseases, such as MCD and FSGS, are by definition not caused by autoantibodies or by 
immune complexes. A major diagnostic feature for both MCD and FSGS is foot process effacement. The 
responsiveness of  these diseases to immunosuppressive treatments such as glucocorticoids, calcineurin 
inhibitors, and mycophenolate has led many to consider these T cell–mediated diseases, even without spe-
cific evidence. The efficacy of  BCDTs in the treatment of  some fraction of  cases, however, supports an 
immune component to these diseases.
In recent years, antibody-independent roles for B cells have emerged as important in several disease 
models. B cells express MHC class II and are excellent antigen-presenting cells. In mouse models of  SLE, 
depletion of  B cells impairs the activation of  autoreactive T cells, suggesting that B cells play important 
roles as antigen-presenting cells (11). Recently, there has been a growing appreciation for the regulatory 
effects of  B cell–derived cytokines, such as IL-10 and IL-35, on attenuating organ-specific autoimmunity in 
experimental autoimmune encephalitis (14, 15). B cells can also make a wide array of  both Th1 and Th2 
cytokines both in vitro (41–45) and in vivo (12, 13).
We and others have suggested that an imbalance between the Rac and Rho G proteins underlies the 
process of  foot process effacement (24, 25, 46). Rho functions to maintain large actin structures important 
for cell adhesion, while Rac functions to stimulate cell migration and membrane ruffling and spreading 
(25, 26). During injury, Rac becomes active and induces the process of  foot process effacement (24). Using 
this knowledge, we used markers of  Rac activation, such as membrane ruffling in cultured podocytes, as a 
surrogate for foot process effacement. We confirmed the effects of  IL-4 on podocytes in situ assay using an 
assay that we developed using minced renal cortices treated ex vivo with cytokines. Our success using these 
assays to identify IL-4 suggests that this assay could also be used to screen for the elusive soluble factors that 
have been speculated to cause nephrotic syndrome (47).
A pathogenic role for cytokine signaling in proteinuric diseases is supported by a recent publication 
describing a transgenic mouse overexpressing JAK2 in podocytes (48). When crossed with the Akita dia-
betic nephropathy mouse model infused with angiotensin II, enhanced proteinuria was observed that was 
largely reversed with JAK2 inhibition. As JAK2 is regulated by cytokines, these data help to link cytokines 
with foot process effacement.
The role of  IL-4 in other glomerular injury models is controversial. It is implicated in the develop-
ment of  proteinuria in models of  graft-versus-host disease (49–51), some models of  SLE (52, 53), and IgA 
nephropathy (54–58) but attenuates proteinuria induced by autologous models of  nephrotoxic nephritis 
(59–63). Given that autologous nephrotoxic nephritis relies on immunization against sheep antibody and 
that IL-4 has direct effects on antibody isotype switching, the role of  IL-4 in nephrotoxic nephritis is com-
plex and not solely dependent on its effect on podocytes.
We are not the first to propose a role of  IL-4 and IL-13 in nephrotic syndrome. IL-4 is secreted by Th2 
helper T cells and associated with atopy, a condition that is highly associated with MCD (64, 65). Trans-
genic mice expressing IL-4 develop glomerulosclerosis (53, 66–68) and transgenic rats expressing IL-13 
develop proteinuria (69). While it was reported previously that podocytes express the IL-4 receptor (IL-4Rα 
and common γ-chain) and can respond to IL-4 (23), attempts to link IL-4 levels in serum and urine with 
nephrotic diseases have been largely unrevealing (70, 71). One possibility is that IL-4 is produced locally at 
levels too low to be detected in blood or urine.
To test whether this was a viable hypothesis, we generated a model that would allow for B cell 
activation in the glomerulus. This suggested that activated B cells could produce enough IL-4 to induce 
proteinuria. Notably, we were unable to detect IL-4 in the serum, showing that local IL-4 can be patho-
genic. While this may not be the mechanism of  disease in humans, it does suggest other potential mech-
anisms. Recent data show that memory lymphocytes can exist as long-term residents of  tissues such 
as lung and skin and far outnumber the number of  lymphocytes circulating in the peripheral immune 
system (72). These cells often function as cytokine-secreting sentinel cells that respond to pathogens 
and/or antigens that transit through organs. Little is known yet about memory lymphocytes or innate 
lymphocytes in kidney, but these specialized cells could be relevant. Finally, polyclonal B cell activators, 
such as TLR ligands, released during infections and trapped by the glomerulus, could be another potent 
stimulus of  B cell activation (73).
We noted that IL-13 was able to induce some level of  membrane ruffling in our in vitro assay. While 
this is consistent with a previous study in rats showing that IL-13 can induce proteinuria, IL-13 plasmid 
administration in mice did not induce proteinuria (data not shown). The reason for the difference between 
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mice and rats remains unknown but may represent species-specific requirements for cytokine-induced pro-
teinuria. Furthermore, the role of  IL-13 in SSNS patients remains unclear (74), as glucocorticoid treatment 
increases serum IL-13 (75).
We directly assessed for IL-4 signaling in kidney biopsies from MCD patients. Biopsies from untreated 
MCD patients are difficult to procure, as patients are often initially treated without biopsy, particularly 
in the United States. Despite this, we identified 29 kidney biopsies of  untreated MCD patients, of  which 
10 had either strongly or weakly positive glomerular staining for activated STAT6. Antibody staining of  
formalin-fixed paraffin-embedded tissue can be challenging, and we were careful to score only for strong 
nuclear staining in glomerular nuclei. This was clear-cut in two of  our samples, as blindly evaluated by 
three pathologists independently. In some of  the samples (8 of  29 patients, 1 of  22 controls), glomerular 
nuclear staining was detected, along with weak cytoplasmic staining in glomerular and/or tubular cells. 
While the cytoplasmic staining likely represents nonspecific background staining, we categorized these 
samples in a separate group. Importantly, both groups of  patients with pSTAT6 staining responded to ste-
roids, consistent with an immune mechanism of  disease.
Most of  our samples did not show pSTAT6, supporting the heterogeneity of  MCD, which may have 
other causes (76–78), such as CLCF1 (47) or ANGPTL4 (78). Additionally, while 90% of  MCD patients 
respond to glucocorticoids (79), most of  these patients will experience a relapse requiring additional thera-
py (79, 80). The identification of  a subset of  patients with MCD due to IL-4 may lead to more personalized 
and specific therapeutic approaches for the treatment of  SSNS. Our work also potentially explains the asso-
ciation of  atopy with MCD as well as the efficacy of  steroids and rituximab in some patients.
Methods
Reagents. Anti-SMPDL3B polyclonal antibody was purchased from Genway (catalog GWB-2281D4). 
Anti-HA (catalog 901501, clone 16B12) antibody, Alexa Fluor 488–conjugated anti-HA (catalog 901509, 
clone 16B12) antibody, Alexa Fluor 488 IgG1, k isotype control (catalog 400132), and Alexa Fluor 647 
mouse IgG2a, k isotype control (catalog 400234) were purchased from Biolegend. Anti-CD20 polyclonal 
antibody (catalog PA5-16701) was purchased from Thermo Fisher Scientific. Anti–β-actin antibody (cata-
log A1978, clone AC-15) was purchased from MilliporeSigma. Rituximab was produced in-house by the 
Antibody Engineering Department at Genentech (81). Alexa Fluor 647–conjugated rituximab was gener-
ated using the Alexa Fluor 647 Antibody Labeling Kit (Thermo Fisher Scientific). Recombinant murine 
IL-13 and TNF-α (Peprotech) and recombinant murine EGF (Cell Signaling Technology) were reconsti-
tuted using the manufacturer’s recommendations. Recombinant murine IL-4, IFN-γ, and anti-mouse IL-4 
monoclonal antibody (clone 11B11) (82) were gifts from Robert Schreiber, Washington University in St. 
Louis. FITC-conjugated anti-HEL monoclonal antibody (clone F10.6.6; Emil Unanue, Washington Uni-
versity School of  Medicine) (83) and nephrotoxic serum (Jeffrey Kopp, National Institute of  Diabetes and 
Digestive and Kidney Diseases, NIH, Bethesda, Maryland, USA) were also provided. FITC-conjugated 
polyclonal anti-mouse C3 F(ab′)2 fragment (catalog 0855510) was purchased from MP Biomedicals. Anti-
pSTAT6 (pTyr641, catalog SAB4300038) polyclonal antibody was purchased from MilliporeSigma. All 
secondary antibodies used purchased from Jackson ImmunoResearch Laboratories Inc.
Mice. Mice were maintained under specific pathogen–free conditions in the Washington University 
School of  Medicine animal facilities according to institutional animal care guidelines. 129X1/SvJ (catalog 
000691), B6.129S2-Ighmtm1Cgn/J (muMT) (84) (catalog 0002288), and B6.129P2-IL4tm1Cgn/J (IL-4–deficient) 
(85) (catalog 0002253) mice were purchased from Jackson Laboratory. HELmuMT (MD4 line) mice (86) 
(originally purchased from Jackson Laboratory, catalog 002595) were provided by Emil Unanue. IL-4–defi-
cient HELmuMT mice were generated in two steps: (a) crossing IL-4–knockout mice to muMT mice to 
produce B cell–deficient, IL-4–deficient mice, and (b) crossing IL-4–deficient, muMT mice with HELmuMT 
to produce IL-4–deficient mice with HEL-transgenic B cells. All mice used were 6- to 8-week-old females.
Generation of  HA-tagged SMPDL3B construct. A mammalian expression construct of  human SMPDL3B 
(pCMV6-XL5 human SMPDL3B transcript variant 1, NM_014474) was purchased from Origene. HA-tag 
(YPYDVPDYA) was inserted downstream of  the signal peptide (aa 1–18) using the QuikChange II XL 
site-directed mutagenesis kit (Agilent) according to the manufacturer’s instructions.
Cell culture and transient transfection. 293T cells (catalog CRL-3216, ATCC) and HeLa cells (catalog 
CCL-2, ATCC) were maintained at 37°C in DMEM supplemented with 10% FBS. 293T cells and HeLa 
cells were transfected using Lipofectamine 2000 and Lipofectamine 3000 (ThermoFisher), respectively, in 
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6-well plates at approximately 70% confluency. Conditionally immortalized murine podocyte cell line gen-
eration and propagation have been previously described (87, 88). Podocytes were propagated at 33˚C (per-
missive temperature) on collagen-I–coated dishes in RPMI, 10% FBS, and 10 U/ml recombinant mouse 
IFN-γ. Differentiation was induced by changing media to RPMI, 5% FBS without IFN-γ, and shifting 
the cells to 37°C (nonpermissive temperature) for at least 7 days. After differentiation, cells arrested their 
growth, increased size, and developed elongated cell processes.
Western blot. Cells were lysed in a modified RIPA lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 5 
mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, cOmplete mini protease inhibitor cocktail [Roche]) 
for 30 minutes on ice. Samples were separated by SDS-PAGE, transferred to nitrocellulose membranes, and 
immunoblotted for SMPDL3B, HA, CD20, and β-actin. The blots were visualized by infrared imaging on 
an Odyssey Imaging System (LI-COR Biosciences). To remove glycan groups, samples were treated with 
PNGase F (New England Biolabs) according to the manufacturer’s instructions prior to SDS-PAGE.
Flow cytometry. The cells were washed with ice-cold PBS and dissociated using a nonenzymatic cell 
dissociation buffer (Thermo Fisher Scientific). For nonfixed cells, cells were directly resuspended in FACS 
buffer (2% FBS and 2 mM EDTA in 1× PBS). For fixed cells, cells were incubated in 4% PFA (Electron 
Microscopy Sciences) in PBS (pH 7.4) for 15 minutes at room temperature, washed 3 times in cold PBS, 
and then resuspended in FACS buffer. Cells were incubated with Alexa Fluor 488–conjugated anti-HA 
antibody (0.5 μg/ml) and Alexa Fluor 647–conjugated rituximab (5 μg/ml) for 30 minutes at 4°C. FACS 
data were collected on a BD LSRFortessa flow cytometer (BD Biosciences) and analyzed with FlowJo 
software (FlowJo).
Light and immunofluorescence microscopy. To confirm membrane localization of  HA-SMPDL3B, 293T 
cells were plated and transfected in Nunc Lab-Tek II CC2 chamber slides (Thermo Fisher Scientific). Cells 
were fixed with 4% PFA in PBS for 15 minutes at room temperature, washed, and stained with Alexa Fluor 
488–conjugated anti-HA antibody (0.5 μg/ml) overnight at 4°C. Coverslips were mounted with ProLong 
Gold Antifade Mountant with DAPI (Thermo Fisher Scientific), and images were captured with a Nikon 
A1R confocal microscope. For H&E staining, kidneys were fixed with 10% buffered formalin solution 
and embedded in paraffin. 5-μm sections were collected and then stained with H&E. Otherwise, kidneys 
were snap frozen in OCT media and 7-μm sections were collected. For immunofluorescence, sections 
were stained with primary antibody for 1 hour at room temperature (anti-HEL = 1:250, anti-Ig = 1:200, 
anti-C3 = 1:200) and treated with the appropriate secondary antibody. Some sections were counterstained 
with Hoechst dye to visualize nuclei. Coverslips were mounted with ProLong Antifade mounting medium 
(Invitrogen), and images were captured with an Olympus FluoView FV1000 microscope. For immunohis-
tochemistry, mice were anesthetized and then perfused with 4% PFA. Kidneys were cryoprotected with 
sucrose solution. Deidentified sections from human kidney biopsies were obtained from the Kidney Trans-
lational Research Core at Washington University in St. Louis, the University of  Michigan, and Guy’s & St. 
Thomas’ Hospital (London, United Kingdom). The diagnosis of  MCD was confirmed by the absence of  
light and immunofluorescence pathology and the presence of  diffuse foot process effacement by transmis-
sion electron microscopy. Control patients included those with the following diagnoses: tubulointerstitial 
nephritis, acute kidney injury in the absence of  glomerular pathology, clean margins from kidneys resect-
ed for renal cell carcinoma, and transplanted donor kidney at the time of  transplant into recipient (off  
of  immunosuppression). Formalin-fixed paraffin-embedded human kidney biopsy sections were subject 
to tris-EDTA antigen retrieval prior to immunostaining. Frozen sections were fixed in 4% PFA. Kidney 
sections were stained with primary antibody (anti-pSTAT6 = 1:100) overnight at +4°C, followed by incu-
bation with secondary antibody. Sections were developed using the DAB Substrate Kit (Thermo Scientific). 
Counterstaining was performed with hematoxylin and 10 mM sodium bicarbonate solution. Sections were 
dehydrated and mounted with VectaMount (Vector Laboratories). Images were obtained using a Nikon 
Eclipse E800 microscope.
Membrane ruff ling assay and kymograph analysis. Murine podocytes were cultured in glass-bottomed 
dishes at 37˚C for 10 days to allow for full differentiation. Eight hours prior to imaging, the cells 
were washed and cultured in serum-free media to arrest any baseline membrane ruffling. Sequential 
images were captured by an Olympus FluoView FV1000 microscope every 10 seconds for a 20-minute 
duration prior to and after cytokine addition. Anti–IL-4 antibody and JAK inhibitor were added to 
podocytes 1 hour prior to IL-4 addition. Olympus Fluoview software was used to assemble movies. 
The ImageJ plug-in, Multiple Kymograph (NIH; http://rsbweb.nih.gov/ij), was used to create kymo-
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graphs at 5 different locations of  maximum membrane ruffling for each cell imaged (89). Ten actin 
spikes were measured for each kymograph, and average length (ruffling index) was determined as 
previously described (27).
Scanning electron microscopy. For visualizing foot processes in minced renal cortices, kidneys were 
harvested from 129X1/SvJ mice and placed in media composed of  RPMI/F12, 15 mM HEPES, 10 
pM PGE1 (MilliporeSigma), 5 μg/ml transferrin (MilliporeSigma), and 10 nM sodium selenate (Mil-
liporeSigma). The cortex of  the kidney was minced using sterile blades and cultured in media with or 
without cytokine or antibody for 20 minutes at 37°C. The tissue was washed in PBS and then fixed in 
0.2 M sodium cacodylate buffer (Electron Microscopy Services) with 2% PFA and 2% glutaraldehyde. 
Samples were post-fixed in 1% phosphate-buffered osmium tetroxide, dehydrated in graded ethanols, 
and critical-point dried in carbon dioxide. The samples were mounted onto stubs and then sputter-coat-
ed using gold/palladium. For all other scanning electron microscopy images, kidneys were harvested 
and cortices were diced and processed as described above. Fifteen glomeruli per sample were analyzed 
using a Hitachi S-2600H scanning electron microscope at the Microscopy and Digital Imaging Core at 
Washington University in St. Louis.
Assessment of  pSTAT6 staining. The stratification of  pSTAT6 staining (negative, weakly positive, and 
strongly positive) was based on these criteria: negative — no nuclear staining or no enhanced nuclear stain-
ing over background (cytoplasmic); weakly positive — enhanced nuclear staining noticeable over back-
ground; and strongly positive — pronounced nuclear staining over background. Two blinded pathologists 
scored all slides for the presence of  pSTAT6 staining.
Intravital 2-photon microscopy. The preparation of  kidney intravital 2-photon microscopy was adapt-
ed from previously described approaches (90–92). Briefly, 8- to 10-week-old mice previously given mul-
timerized HEL were anesthetized with isofluorane and a small vertical incision was made in the flank 
of  the mouse. The kidney was exposed, and an upper chamber plate painted with a thin ring of  VetBond 
tissue adhesive (3M) was gently lowered on to the kidney to secure it to the cover glass and seal the 
peritoneal cavity. A dual-channel heating system (Warner Instruments) warmed the imaging chamber 
to 37°C. CFSE-labeled HEL-specific B cells were then transferred by tail vein injection, followed with 
2,000 kD Rhodamine dextran to label vessels and glomeruli. Time-lapse imaging was performed using a 
custom-built 2-photon microscope and ImageWarp acquisition software (A&B Software). Images were 
acquired either at video rate (30 f/sec) or by time-lapse imaging, where we averaged 15 video-rate 
frames (0.5 s/slice) creating a Z-stack of  31 sequential Z-steps (2.5 μm each). Each optical section was 
approximately 220 × 240 μm in the x and y dimensions.
IL-4 piggyBac plasmid construction, hydrodynamic injection, and tofacitinib administration. Plasmid encod-
ing murine IL-4 was a gift from Ken Murphy (Washington University in St. Louis). IL-4 was amplified 
and cloned into the PB530A-2 vector (System Biosciences) using BamHI and NotI. The piggyBac/IL-4 
and transposase vectors were prepped using the Qiagen EndoFree Plasmid Maxi Kit and combined at 
a 5:1 ratio (total DNA = 45 μg) in approximately 2 ml TransIT QR Hydrodynamic Delivery Solution 
(Mirus Bio). Hydrodynamic injection of  these vectors occurred through the tail vein using a 30-gauge 
needle. Serum IL-4 was determined using the Mouse IL-4 Quantikine ELISA Kit (R&D Systems). For the 
JAK inhibitor experiments, tofacitinib (Selleckchem) was mixed with 0.5% methylcellulose and 0.025% 
Tween-20 in water, and 50 mg/kg was administered by oral gavage to mice twice daily.
Assessment of  proteinuria. For SDS-PAGE analysis, 5 μl urine was loaded with ×4 Laemmli sample buf-
fer onto a 4%–20% SDS polyacrylamide gel (Bio-Rad). Proteins were visualized by staining the gel with 
Coomassie blue. For quantification, the Mouse Albumin ELISA Quantification Set (Bethyl Laboratories 
Inc.) and QuantiChrom Creatinine Assay Kit (Bioassay Systems) were used using manufacturer’s directions.
Production of  multimerized HEL and injection into mice. HEL (Amresco) was dissolved in sterile PBS 
(Hyclone) and treated with NHS-biotin (Thermo Scientific), followed with dialysis using Slide-A-Lyzer 
Dialysis Cassettes G2 (Thermo Scientific) against sterile PBS. Avidin (Invitrogen) was slowly added to 
the solution of  biotinylated HEL to generate multimerized HEL. The size of  multimerized HEL was con-
firmed using SDS-PAGE, followed by Coomassie blue staining. Multimerized HEL (1 mg) was delivered 
i.v. via tail vein injection into mice, and organs were harvested 30 minutes to 7 days after infusion.
HEL-specific B cell isolation, polarization, CFSE labeling, and adoptive transfer into mice. Spleens from 
HELmuMT or IL-4–deficient HELmuMT mice were collected into a cell strainer (100-μm nylon mesh) 
and mashed through. Splenocytes were washed and resuspended in PBS supplemented with 2% FBS 
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and 2 mM EDTA. B cells were enriched by negative isolation using the Dynabeads Mouse CD43 
(Untouched B cells) Isolation Kit (Invitrogen). B cell purity was validated by flow cytometry (using 
B220 as the B cell marker), and consistently was >95%. Unpolarized B cells were polarized into IL-4–
secreting B cells as previously described (13, 36). Purified HEL-specific B cells were CFSE-labeled per 
the manufacturer’s instructions (CellTrace CFSE Cell Proliferation Kit, Molecular Probes/Invitrogen). 
5 × 106 B cells were transferred via tail vein injection into wild-type hosts previously administered mul-
timerized HEL.
Statistics. All data, except for pSTAT6 characterization data, are represented as mean ± SD. For mem-
brane ruffling results, group differences were assessed by repeated-measures 1-way ANOVA with Bonfer-
roni correction. For pSTAT6 characterization, Fisher’s exact test was used. For all other results, 2-tailed 
Mann-Whitney test was used. A P value of  less than 0.05 was considered significant.
Study approval. All animal experiments were conducted with approval from the Washington University 
in St. Louis Animal Care and Use Committee (St. Louis, Missouri, USA). Patient samples were obtained 
in a deidentified manner, with institutional review board approval from King’s College/Evelina Children’s 
Hospital, the Kidney Translational Research Core (Washington University in St. Louis), and the University 
of  Michigan.
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